NCT01577251

Brief Summary

The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8,000

participants targeted

Target at P75+ for all trials

Timeline
56mo left

Started Jun 2008

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Jun 2008Dec 2030

Study Start

First participant enrolled

June 1, 2008

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

April 12, 2012

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 13, 2012

Completed
18.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

March 4, 2026

Status Verified

March 1, 2026

Enrollment Period

22.5 years

First QC Date

April 12, 2012

Last Update Submit

March 3, 2026

Conditions

Neoplasia

Outcome Measures

Primary Outcomes (1)

  • Health Assessments

    10 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy

* Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy * Able to sign consent

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (4)

Virtua Samson Cancer Center

Moorestown, New Jersey, 08057, United States

NOT YET RECRUITING

Virtua Health & Wellness Center

Voorhees Township, New Jersey, 08043, United States

RECRUITING

Lancaster General Hospital

Lancaster, Pennsylvania, 17604, United States

RECRUITING

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Plasma, serum and buffy coat are collected and stored in -80 degree Celsius freezer for future biomarker studies.

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Jay Dorsey, MD, PhD

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Project Manager

CONTACT

radonccru@pennmedicine.upenn.edu

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2012

First Posted

April 13, 2012

Study Start

June 1, 2008

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2030

Last Updated

March 4, 2026

Record last verified: 2026-03

Locations

US(4)